ArticleJournal of translational medicine2026
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models.
Matteo Villa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.